Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures
Introduction
Head & neck squamous cell carcinoma (HNSCC) is the most frequent cancer derived from the aero-digestive tract. Patients with end stage (stage III–IV) and recurrent disease have a very poor prognosis when radiotherapy and/or surgery are no longer an option. Malignant melanoma (MM) is also a poorly controllable disease once it has reached an advanced stage. Unlike HNSCC, MM is often asymptomatic which allows for a disease spread prior to diagnosis. In spite of massive experimental clinical trials in both patient groups, survival has not improved significantly over the past two decades. Meanwhile, a recent phase III clinical trial has shown promising results in MM patients treated with Ipilimumab (CTLA-4 antibody) by significantly increased survival in the Ipilimumab treated patient group [1]. Although the molecular and cellular background for efficacy is largely unknown these data suggest that manipulation with cellular suppressive mechanisms may tip the balance from immune tolerance of cancer towards immunological attack.
Tumors are frequently infiltrated by cells of the immune system, which controls tumor growth at an early stage. Due to genetic instability the tumor cells undergo mutations leading to escape variants and progression [2]. In addition the tumor acquires immune suppressive mechanisms at a cellular (Treg [3], MDSC [4]), soluble (TH2 cytokines) and metabolic (ex. IDO [5]) level. Thereby the tumor environment is skewed towards a tolerogenic state.
In an attempt to tip the balance towards a tumor immunogenic state, different approaches of cancer immunotherapy have been tested including administration of cytokines and therapeutic vaccination. To the latter, although measurable immune responses were induced, limited clinical responses were obtained. However, recent studies in adoptive T-cell therapy have shown very promising results where 50% of MM patients with advanced disease obtained long lasting clinical objective responses after preconditioning lymphodepletion, infusion of ex vivo expanded tumor infiltrating lymphocytes (TILs) and high dose IL-2 [6]. TILs comprised T-cell populations with specificity towards autologous tumor, serving as a source of unknown tumor associated antigens (TAAs) [7]. Regarding identification of TAA peptide antigen specific T-cells among TILs, most attention has been directed at single epitopes derived from differentiation antigens such as MART-1 in MM patients. Thus, the antigen specific repertoire of TILs remains unknown and further attention is needed to identify tumor targets of potential clinical importance in adoptive T-cell therapy.
On the basis of the published methods from Dudley et al. we have established a method for successful expansion of TILs from both MM and HNSCC patients [8]. This has let us to initiate clinical pilot trials in MM patients (NCT00937625) and HNSCC patients (NCT00937300).
To identify the TAA specific populations in the TILs, we screened for reactivity against a panel of peptides covering three main categories of over expressed (OE), cancer testis (CT) and differentiation (D) TAAs. Belonging to the first category, the BCL-2 family proteins (Mcl-1, Bcl-2 and Bclx L) and survivin inhibits apoptosis and are in many cases crucial for tumor cell survival [9], [10], [11], [12]. Telomerase is another over expressed protein that ensures the capacity of cancer cells to continued proliferation [13], [14], while cyclin B1 ensures sustained mitosis [15], [16] and RhoC facilitates increased metastatic potential [17], [18]. Cancer testis antigens (CT) (MAGE 1, MAGE 3 and NY ESO-1) are silenced in normal tissue and upregulated in MM [19] and HNSCC [20], [21], rendering them suited targets for immune recognition. Finally, the differentiation antigen MART-1 is recognized as a highly immunogenic target in MM [22]. Specific T-cell populations for all the included peptides have previously been identified in the circulation of cancer patients. Here we show an occurrence of a broad repertoire of TAA specific T-cell populations from multiple individually established TIL cultures from MM and HNSCC patients. Although there is a tendency of an unequal distribution of TAA specific subgroups between TIL cultures and between patients, there is an equal broad representation of responses towards over expressed antigens (e.g. cyclin B1 and Bcl-x) and cancer testis antigens (e.g. NY ESO-1) in both patient categories.
Section snippets
Patients
Patients referred to surgery for primary or recurrent stage II–IV malignant melanoma or oral squamous cell carcinoma were eligible for the study. The study protocol was approved by the Local ethics committee and all patients were included after signing informed consent. Tumor material from the patients was obtained from the surgically removed tumor and processed for culturing within 30 min after surgery.
Tumor infiltrating lymphocytes (TILs)
TILs were generated accordingly to a previously described two-step expansion method
Patients
We examined the occurrence of TAA peptide specific T-cell populations, determined by IFNγ release measurement in Elispot, in ex vivo expanded TIL cultures from six HNSCC and six MM patients. In HNSCC (two HLA-A2+, three HLA-A3+ and one HLA-A2/A3+), all patients showed TAA specific responses in both alleles. In MM (four HLA-A2+ and two HLA-A3+), 5/6 (83%) patients responded in both alleles. Patient characteristics are summarized in Table 2.
TIL cultures
Lymphocytes migrated out from the fragments within two
Discussion
In recent years adoptive T-cell therapy has gained increased attention, due to the capacity of this treatment to mediate significant clinical responses, including partial or complete responses in heavily pre-treated patients by restoring the immunogenicity of tumors in melanoma patients. The most consistent objective response rates are obtained by infusion of ex vivo expanded autologous TIL bulk cultures supported by immune conditioning [29], [30], [31]. However, very little is known about the
Disclosures
No conflicts of interests to declare.
Acknowledgments
We would like to extend our appreciation of the excellent technical assistance from Mette Noe Vitting and Charlotte Vajhøj on TIL expansion, Kirsten Nikolajsen for flow cytometry analysis, and to Tobias Wirenfeldt Klausen for statistical assistance. The study was supported by the Danielsen Foundation, The Danish Cancer Society, Danish Medical Research Council, and Herlev University Hospital.
References (46)
- et al.
Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression
Semin. Cancer Biol.
(2006) - et al.
Bimodal ex vivo Expansion of T-cells from patients with Head & Neck Squamous Cell arcinoma: a prerequisite for adoptive cell transfer
Cytotherapy
(2011) - et al.
Immunogenicity of Bcl-2 in patients with cancer
Blood
(2005) - et al.
The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes
Immunity
(1999) - et al.
Tumor infiltrating lymphocytes in melanoma comprise high numbers of T-cell clonotypes that are lost during in vitro culture
Clin. Immunol.
(2000) - et al.
Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53
Mol. Immunol.
(2002) - et al.
Sinks Suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy
Trends Immunol.
(2005) - et al.
Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy
Blood
(2005) - et al.
Improved survival with ipilimumab in patients with metastatic melanoma
N. Engl. J. Med.
(2010) - et al.
Cancer immunoediting: from immunosurveillance to tumor escape
Nat. Immunol.
(2002)
Regulatory T cells in tumor immunity
Int. J. Cancer
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
J. Clin. Invest
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
J. Clin. Oncol.
In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2
J. Clin. Oncol.
Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients
Cancer Res.
The antiapoptotic member of the Bcl-2 family Mcl-1 is a CTL target in cancer patients
Leukemia
Spontaneous immunity against Bcl-xL in cancer patients
J. Immunol.
The immunogenicity of the hTERT540–548 peptide in cancer
Clin. Cancer Res.
Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells
J. Exp. Med.
Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors
Cancer Immunol. Immunother.
Genomic analysis of metastasis reveals an essential role for RhoC
Nature
RhoC a new target for therapeutic vaccination against metastatic cancer
Cancer Immunol. Immunother.
Cancer/testis (CT) antigens: potential targets for immunotherapy
Cancer Sci.
Cited by (21)
CAR-T cells and combination therapies: What's next in the immunotherapy revolution?
2018, Pharmacological ResearchCitation Excerpt :The presence of naturally occurring tumor-reactive T cells has been thoroughly documented in the peripheral blood, and within the tumors, of cancer patients [1–5].
Methods to improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion
2013, Journal of Investigative DermatologyCitation Excerpt :Previous studies have shown that IFN-γ differently modulates the sensitivity of melanoma cells to cytolytic T-cell clones recognizing distinct antigens, and does not increase melanoma killing by clones specific for differentiation antigens (Kirkin et al., 1996). However, we have recently shown that clinically relevant TIL products contain a variety of T cells specific not only for differentiation antigens but also for cancer-testis, mutation, and overexpressed tumor antigens (Andersen et al., 2012; Junker et al., 2012). Altogether, these data suggest that T-cell responses of TIL products might be increased with immuno-sensitizing agents.
Adoptive T cell therapy for solid tumors: current landscape and future challenges
2024, Frontiers in ImmunologyNovel Immunotherapies for Osteosarcoma
2022, Frontiers in OncologyThe Adaptome as Biomarker for Assessing Cancer Immunity and Immunotherapy
2020, Methods in Molecular Biology